Phillip O. Coffin, MD
Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, California; Division of ID, HIV, & Global Medicine, University of California San Francisco, San Francisco, California
Original Research
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
July 30, 2025
Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
